Back to News
Market Impact: 0.25
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
Agenus is concentrating BOT/BAL’s registration strategy on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable colon cancer. The company ended funding for BATTMAN, which studied later-line metastatic disease; the article provides no trial results or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
AGEN-0.30
More News
- Australian data center operator NextDC's shares plunge 40% after it slashes earnings forecast
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Neoclouds Lose Silver Lining as Elice, CoreWeave Dive: Evening Briefing Americas
- Anthropic May Spend $750 Billion on Computing Costs, WSJ Reports
- This Janus Henderson fund manager owns CoreWeave debt — here's why he's sticking with it
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally